We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports ...

Bullish option flow detected in Gilead (GILD) with 4,231 calls trading, 1.7x expected, and implied vol increasing almost 2 points to 28.65%.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

Gilead Sciences (NASDAQ:GILD – Get Free Report) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Gilead Sciences to post earnings of $1.66 ...

The upcoming report from Gilead Sciences (GILD) is expected to reveal quarterly earnings of $1.58 per share, indicating a decline of 31% compared to the year-ago period. Analysts forecast revenues of ...

The HIV Community Scholars, supported by Gilead Sciences, are invited to attend APCS 2024 to present their innovative ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Creative Financial Designs Inc. ADV boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.4% during the third quarter, HoldingsChannel.com reports. The institutional investor ...